Andrea Mariani1, Chen Wang2, Ann L Oberg3, Shaun M Riska3, Michelle Torres1, Joseph Kumka4, Francesco Multinu1, Gunisha Sagar4, Debarshi Roy4, Deok-Beom Jung4, Qing Zhang1, Tommaso Grassi1, Daniel W Visscher4, Vatsal P Patel4, Ling Jin4, Julie K Staub4, William A Cliby1, Saravut J Weroha5, Kimberly R Kalli5, Lynn C Hartmann5, Scott H Kaufmann6, Ellen L Goode3, Viji Shridhar7. 1. Department of Obstetrics and Gynecology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 2. Department of Obstetrics and Gynecology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 3. Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 4. Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 5. Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 6. Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 7. Department of Obstetrics and Gynecology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address: shridhar.vijayalakshmi@mayo.edu.
Abstract
OBJECTIVE: This study is designed to identify genes and pathways that could promote metastasis to the bowel in high-grade serous ovarian cancer (OC) and evaluate their associations with clinical outcomes. METHODS: We performed RNA sequencing of OC primary tumors (PTs) and their corresponding bowel metastases (n = 21 discovery set; n = 18 replication set). Differentially expressed genes (DEGs) were those expressed at least 2-fold higher in bowel metastases (BMets) than PTs in at least 30% of patients (P < .05) with no increased expression in paired benign bowel tissue and were validated with quantitative reverse transcription PCR. Using an independent OC cohort (n = 333), associations between DEGs in PTs and surgical and clinical outcomes were performed. Immunohistochemistry and mouse xenograft studies were performed to confirm the role of LRRC15 in promoting metastasis. RESULTS: Among 27 DEGs in the discovery set, 21 were confirmed in the replication set: SFRP2, Col11A1, LRRC15, ADAM12, ADAMTS12, MFAP5, LUM, PLPP4, FAP, POSTN, GRP, MMP11, MMP13, C1QTNF3, EPYC, DIO2, KCNA1, NETO1, NTM, MYH13, and PVALB. Higher expression of more than half of the genes in the PT was associated with an increased requirement for bowel resection at primary surgery and an inability to achieve complete cytoreduction. Increased expression of LRRC15 in BMets was confirmed by immunohistochemistry and knockdown of LRRC15 significantly inhibited tumor progression in mice. CONCLUSIONS: We identified 21 genes that are overexpressed in bowel metastases among patients with OC. Our findings will help select potential molecular targets for the prevention and treatment of malignant bowel obstruction in OC. Published by Elsevier Inc.
OBJECTIVE: This study is designed to identify genes and pathways that could promote metastasis to the bowel in high-grade serous ovarian cancer (OC) and evaluate their associations with clinical outcomes. METHODS: We performed RNA sequencing of OC primary tumors (PTs) and their corresponding bowel metastases (n = 21 discovery set; n = 18 replication set). Differentially expressed genes (DEGs) were those expressed at least 2-fold higher in bowel metastases (BMets) than PTs in at least 30% of patients (P < .05) with no increased expression in paired benign bowel tissue and were validated with quantitative reverse transcription PCR. Using an independent OC cohort (n = 333), associations between DEGs in PTs and surgical and clinical outcomes were performed. Immunohistochemistry and mouse xenograft studies were performed to confirm the role of LRRC15 in promoting metastasis. RESULTS: Among 27 DEGs in the discovery set, 21 were confirmed in the replication set: SFRP2, Col11A1, LRRC15, ADAM12, ADAMTS12, MFAP5, LUM, PLPP4, FAP, POSTN, GRP, MMP11, MMP13, C1QTNF3, EPYC, DIO2, KCNA1, NETO1, NTM, MYH13, and PVALB. Higher expression of more than half of the genes in the PT was associated with an increased requirement for bowel resection at primary surgery and an inability to achieve complete cytoreduction. Increased expression of LRRC15 in BMets was confirmed by immunohistochemistry and knockdown of LRRC15 significantly inhibited tumor progression in mice. CONCLUSIONS: We identified 21 genes that are overexpressed in bowel metastases among patients with OC. Our findings will help select potential molecular targets for the prevention and treatment of malignant bowel obstruction in OC. Published by Elsevier Inc.
Authors: Chen Wang; Sebastian M Armasu; Kimberly R Kalli; Matthew J Maurer; Ethan P Heinzen; Gary L Keeney; William A Cliby; Ann L Oberg; Scott H Kaufmann; Ellen L Goode Journal: Clin Cancer Res Date: 2017-03-09 Impact factor: 12.531
Authors: J M Lancaster; H K Dressman; J P Clarke; R A Sayer; M A Martino; J M Cragun; A H Henriott; J Gray; R Sutphen; A Elahi; R S Whitaker; M West; J R Marks; J R Nevins; A Berchuck Journal: Int J Gynecol Cancer Date: 2006 Sep-Oct Impact factor: 3.437
Authors: M A Price; M L Bell; D W Sommeijer; M Friedlander; M R Stockler; A Defazio; P M Webb; P N Butow Journal: Gynecol Oncol Date: 2013-04-08 Impact factor: 5.482
Authors: Krishna R Kalari; Asha A Nair; Jaysheel D Bhavsar; Daniel R O'Brien; Jaime I Davila; Matthew A Bockol; Jinfu Nie; Xiaojia Tang; Saurabh Baheti; Jay B Doughty; Sumit Middha; Hugues Sicotte; Aubrey E Thompson; Yan W Asmann; Jean-Pierre A Kocher Journal: BMC Bioinformatics Date: 2014-06-27 Impact factor: 3.169
Authors: Syed Mohammed Musheer Aalam; Xiaojia Tang; Jianning Song; Upasana Ray; Stephen J Russell; S John Weroha; Jamie Bakkum-Gamez; Viji Shridhar; Mark E Sherman; Connie J Eaves; David J H F Knapp; Krishna R Kalari; Nagarajan Kannan Journal: NAR Cancer Date: 2022-07-22
Authors: Upasana Ray; Christopher L Pathoulas; Prabhu Thirusangu; James W Purcell; Nagarajan Kannan; Viji Shridhar Journal: Cancer Res Date: 2022-05-03 Impact factor: 13.312
Authors: Upasana Ray; Deok-Beom Jung; Ling Jin; Yinan Xiao; Subramanyam Dasari; Sayantani Sarkar Bhattacharya; Prabhu Thirusangu; Julie K Staub; Debarshi Roy; Bhaskar Roy; S John Weroha; Xiaonan Hou; James W Purcell; Jamie N Bakkum-Gamez; Scott H Kaufmann; Nagarajan Kannan; Anirban K Mitra; Viji Shridhar Journal: Cancer Res Date: 2022-03-15 Impact factor: 13.312